Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit

Precision Biologics Set to Unveil PB-223 ADC at ACE Drug Discovery Summit

Precision Biologics, Inc., a company renowned for its innovative approach to cancer treatment, is gearing up to present significant findings regarding its new antibody-drug conjugate (ADC), known as PB-223. This groundbreaking work will be officially highlighted by CEO Dr. Philip M. Arlen at the upcoming 6th ACE Drug Discovery Summit, taking place on February 19, 2026, in London, UK.

Overview of the Presentation

Dr. Arlen's presentation, titled "PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 glycans in Solid Tumors," promises to share compelling data on the in vitro and in vivo efficacy of PB-223. The ADC has demonstrated specific anti-tumor activity against several human cancer types that express truncated core 2 O-glycans, marking a significant advancement in targeted cancer therapies.

At the presentation, Dr. Arlen will delve into the details of PB-223's preclinical studies which illustrate its effectiveness with reduced toxicity, a vital consideration in cancer treatment. The results have shown that PB-223 can selectively target tumor cells while sparing healthy tissue, which greatly enhances its potential as a therapeutic option.

Data Insights

In the lead-up to the summit, Precision Biologics has generated excitement within the scientific community with their preliminary data. Notable findings include the eradication of tumors in animal models with minimal toxicity observed in subsequent blood and tissue analyses. These results indicate a promising path toward clinical trials that could lead to the drug's approval for human use.

“This ADC offers exquisite sensitivity and specificity, maximizing the anti-tumor response while minimizing side effects,” Dr. Arlen stated. This groundbreaking approach targets a wide range of solid tumors, presenting a significant leap forward in developing cancer therapies with enhanced safety profiles.

Event Details

Title: PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 glycans in Solid Tumors
Date/Time: February 19, 2026, from 12:00 PM to 12:30 PM
Location: The Insurance Hall, 20-21 Aldermanbury, London, UK
Keynote Speaker: Dr. Philip M. Arlen, President & CEO, Precision Biologics, Inc.

Concluding Thoughts

This presentation not only serves as a platform for unveiling the advantages of PB-223 but also positions Precision Biologics at the forefront of cancer research and treatment innovation. As the scientific community becomes increasingly interested in the potential of PB-223, the hope is that such advancements will translate into effective, safe treatments for patients battling various forms of cancer. The full data presentation will mark a significant milestone for the company, offering a comprehensive overview of their findings thus far.

Precision Biologics continues to work diligently, aiming to move this promising drug towards clinical trials and eventual public availability, furthering its mission to combat cancer with cutting-edge science.